Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

Sten Madsbad; Thure Krarup; Carolyn F Deacon; Jens Juul Holst; Sten Madsbad; Thure Krarup; Carolyn F Deacon; Jens J Holst

doi:10.1097/MCO.0b013e328302f414

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

Sten Madsbad, Thure Krarup, Carolyn F Deacon, Jens Juul Holst, Sten Madsbad, Thure Krarup, Carolyn F Deacon, Jens J Holst

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

86 Citationer (Scopus)

Abstract

Udgivelsesdato: 2008-Jul

Originalsprog	Engelsk
Tidsskrift	Current Opinion in Clinical Nutrition and Metabolic Care
Vol/bind	11
Udgave nummer	4
Sider (fra-til)	491-9
Antal sider	8
ISSN	1363-1950
DOI	https://doi.org/10.1097/MCO.0b013e328302f414 https://doi.org/10.1097/MCO.0b013e328302f414
Status	Udgivet - 2008

Bibliografisk note

Keywords: Adamantane; Antigens, CD26; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Triazoles; Venoms

Adgang til dokumentet

Citationsformater

Madsbad, S., Krarup, T., Deacon, C. F., Holst, J. J., Madsbad, S., Krarup, T., Deacon, C. F., & Holst, J. J. (2008). Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current Opinion in Clinical Nutrition and Metabolic Care, 11(4), 491-9. https://doi.org/10.1097/MCO.0b013e328302f414, https://doi.org/10.1097/MCO.0b013e328302f414

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. / Madsbad, Sten; Krarup, Thure; Deacon, Carolyn F et al.
I: Current Opinion in Clinical Nutrition and Metabolic Care, Bind 11, Nr. 4, 2008, s. 491-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Madsbad, S, Krarup, T, Deacon, CF , Holst, JJ , Madsbad, S, Krarup, T, Deacon, CF & Holst, JJ 2008, 'Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials', Current Opinion in Clinical Nutrition and Metabolic Care, bind 11, nr. 4, s. 491-9. https://doi.org/10.1097/MCO.0b013e328302f414, https://doi.org/10.1097/MCO.0b013e328302f414

@article{a9cf19e0ab4811ddb5e9000ea68e967b,

title = "Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials",

abstract = "PURPOSE OF REVIEW: To discuss the virtues and shortcomings of the glucagon-like peptide-1 receptor agonists and the dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes. RECENT FINDINGS: The injectable glucagon-like peptide-1 receptor agonists exenatide significantly improves glycaemic control, with average reductions in haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, and causes a weight loss of approximately 2-3 kg after 30 weeks of treatment in patients with type 2 diabetes. The adverse effects are transient nausea and vomiting. The long-acting glucagon-like peptide-1 receptor agonists liraglutide and exenatide long-acting release reduce haemoglobin A1c by about 1.0-2.0% and have fewer gastrointestinal side-effects. The orally available dipeptidyl peptidase-4 inhibitors, that is sitagliptin and vildagliptin reduce haemoglobin A1c by 0.5-1.0%, are weight neutral and without gastrointestinal side-effects. SUMMARY: The benefits and position of the glucagon-like peptide-1 analogues and the dipeptidyl peptidase-4 inhibitors in the diabetes treatment algorithm will be clarified when we have long-term trials with hard cardiovascular endpoints and data illustrating the effects on the progression of type 2 diabetes.",

author = "Sten Madsbad and Thure Krarup and Deacon, {Carolyn F} and Holst, {Jens Juul} and Sten Madsbad and Thure Krarup and Deacon, {Carolyn F} and Holst, {Jens J}",

note = "Keywords: Adamantane; Antigens, CD26; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Triazoles; Venoms",

year = "2008",

doi = "10.1097/MCO.0b013e328302f414",

language = "English",

volume = "11",

pages = "491--9",

journal = "Current Opinion in Clinical Nutrition and Metabolic Care",

issn = "1363-1950",

publisher = "Lippincott Williams & Wilkins",

number = "4",

}

TY - JOUR

T1 - Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

AU - Madsbad, Sten

AU - Krarup, Thure

AU - Deacon, Carolyn F

AU - Holst, Jens Juul

AU - Madsbad, Sten

AU - Krarup, Thure

AU - Deacon, Carolyn F

AU - Holst, Jens J

N1 - Keywords: Adamantane; Antigens, CD26; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Triazoles; Venoms

PY - 2008

Y1 - 2008

N2 - PURPOSE OF REVIEW: To discuss the virtues and shortcomings of the glucagon-like peptide-1 receptor agonists and the dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes. RECENT FINDINGS: The injectable glucagon-like peptide-1 receptor agonists exenatide significantly improves glycaemic control, with average reductions in haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, and causes a weight loss of approximately 2-3 kg after 30 weeks of treatment in patients with type 2 diabetes. The adverse effects are transient nausea and vomiting. The long-acting glucagon-like peptide-1 receptor agonists liraglutide and exenatide long-acting release reduce haemoglobin A1c by about 1.0-2.0% and have fewer gastrointestinal side-effects. The orally available dipeptidyl peptidase-4 inhibitors, that is sitagliptin and vildagliptin reduce haemoglobin A1c by 0.5-1.0%, are weight neutral and without gastrointestinal side-effects. SUMMARY: The benefits and position of the glucagon-like peptide-1 analogues and the dipeptidyl peptidase-4 inhibitors in the diabetes treatment algorithm will be clarified when we have long-term trials with hard cardiovascular endpoints and data illustrating the effects on the progression of type 2 diabetes.

AB - PURPOSE OF REVIEW: To discuss the virtues and shortcomings of the glucagon-like peptide-1 receptor agonists and the dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes. RECENT FINDINGS: The injectable glucagon-like peptide-1 receptor agonists exenatide significantly improves glycaemic control, with average reductions in haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, and causes a weight loss of approximately 2-3 kg after 30 weeks of treatment in patients with type 2 diabetes. The adverse effects are transient nausea and vomiting. The long-acting glucagon-like peptide-1 receptor agonists liraglutide and exenatide long-acting release reduce haemoglobin A1c by about 1.0-2.0% and have fewer gastrointestinal side-effects. The orally available dipeptidyl peptidase-4 inhibitors, that is sitagliptin and vildagliptin reduce haemoglobin A1c by 0.5-1.0%, are weight neutral and without gastrointestinal side-effects. SUMMARY: The benefits and position of the glucagon-like peptide-1 analogues and the dipeptidyl peptidase-4 inhibitors in the diabetes treatment algorithm will be clarified when we have long-term trials with hard cardiovascular endpoints and data illustrating the effects on the progression of type 2 diabetes.

U2 - 10.1097/MCO.0b013e328302f414

DO - 10.1097/MCO.0b013e328302f414

M3 - Journal article

SN - 1363-1950

VL - 11

SP - 491

EP - 499

JO - Current Opinion in Clinical Nutrition and Metabolic Care

JF - Current Opinion in Clinical Nutrition and Metabolic Care

IS - 4

ER -